{"id":103672,"date":"2026-03-09T07:48:29","date_gmt":"2026-03-09T07:48:29","guid":{"rendered":"https:\/\/www.mymsd.ch\/fr\/?page_id=103672"},"modified":"2026-03-10T08:20:42","modified_gmt":"2026-03-10T08:20:42","slug":"noxafil","status":"publish","type":"page","link":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/","title":{"rendered":"Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole)"},"content":{"rendered":"\n<h1 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--ff9ac87acecc48e63ea05dd59be9cef5\"><mark class=\"has-inline-color has-teal-500-color\">Information professionnelle abr\u00e9g\u00e9e de NOXAFIL<sup>\u00ae<\/sup> (posaconazole)<\/mark><\/h1>\n\n\n\n<p class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--a964bf4a3e376bf850c63c5ca1305094\"><strong>NOXAFIL<sup>\u00ae<\/sup>: PA: <\/strong>Posaconazole. <strong>I: <\/strong>Pr\u00e9vention des infections fongiques invasives, y compris par des levures et moisissures, chez des patients d\u00e8s l\u2019\u00e2ge de 13 ans (comprim\u00e9s\/suspension orale) resp. d\u00e8s 2 ans (perfusion) pr\u00e9sentant un risque \u00e9lev\u00e9 de survenue de ce type d\u2019infection. Traitement (adultes ou d\u00e8s l&rsquo;age de 2 ans pour la perfusion)\u00a0: fusariose lors de r\u00e9sistance ou d\u2019intol\u00e9rance \u00e0 l\u2019amphot\u00e9ricine B ; chromoblastomycose\/myc\u00e9tome lors de r\u00e9sistance ou d\u2019intol\u00e9rance \u00e0 l\u2019itraconazole ; coccidio\u00efdomycose lors de r\u00e9sistance ou d\u2019intol\u00e9rance \u00e0 l\u2019amphot\u00e9ricine B, \u00e0 l\u2019itraconazole, au fluconazole. <strong>Po: <\/strong><em><u>Comprim\u00e9s:<\/u> <\/em>pr\u00e9vention des infections fongiques invasives\/traitement des infections fongiques invasives r\u00e9fractaires : dose initiale de 300 mg (3x 100 mg) 2x par jour le premier jour, puis 300 mg (3x 100 mg) 1x par jour les jours suivants ; prise ind\u00e9pendante des repas. <em><u>Suspension orale:<\/u> <\/em>pr\u00e9vention : 200 mg (5 ml) 3x par jour ; prise aux repas ou avec un compl\u00e9ment alimentaire. Infections fongiques invasives r\u00e9fractaires (IFI)\/IFI avec intol\u00e9rance : 400 mg (10 ml) 2x par jour. 200 mg (5 ml) 4x par jour chez les patients incapables de prendre des repas\/compl\u00e9ments alimentaires<em>. <u>Solution pour perfusion:<\/u> <\/em>dose initiale de 300 mg 2x par jour le premier jour, puis 300 mg 1x par jour les jours suivants, en perfusions d\u2019au moins 90 minutes par voie veineuse centrale. Enfants de 2 \u00e0 &lt;12 ans : 1er jour 2x 6mg\/kg par jour, \u00e0 partir du 2\u00e8me jour 1x 6mg\/kg par jour jusqu&rsquo;\u00e0 une dose unique maximale de 300mg. Adolescents de 12 \u00e0 &lt;18 ans : 1er jour 2x 4,5 mg\/kg par jour, \u00e0 partir du 2\u00e8me jour 1x 4,5 mg\/kg par jour jusqu&rsquo;\u00e0 une dose unique maximale de 300 mg. Si n\u00e9cessaire augmenter jusqu&rsquo;\u00e0 6mg\/kg. Prudence chez les patients pesant moins de 60 kg : risque d\u2019un taux accru de posaconazole susceptible de causer une toxicit\u00e9 accrue. Attention particuli\u00e8re chez les patients pesant plus de 120 kg : l\u2019exposition au posaconazole est \u00e9ventuellement r\u00e9duite. Dur\u00e9e de la pr\u00e9vention : d\u00e9pend du r\u00e9tablissement apr\u00e8s la neutrop\u00e9nie ou l\u2019immunosuppression. Chez les patients pr\u00e9sentant une leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb ou des syndromes my\u00e9lodysplasiques, la pr\u00e9vention doit \u00eatre mise en place quelques jours avant le d\u00e9but escompt\u00e9 de la neutrop\u00e9nie et poursuivi pendant 7 jours apr\u00e8s l\u2019augmentation du nombre de neutrophiles \u00e0 &gt;500 cellules par mm3. La dur\u00e9e du traitement est bas\u00e9e sur la s\u00e9v\u00e9rit\u00e9 de la maladie de fond, l\u2019\u00e9tat de r\u00e9cup\u00e9ration apr\u00e8s l\u2019immunosuppression et la r\u00e9ponse clinique. Un contr\u00f4le du principe actif th\u00e9rapeutique est recommand\u00e9. <strong>CI: <\/strong>Utilisation concomitante d\u2019alcalo\u00efdes de l\u2019ergot de seigle, de substrats du CYP3A4, d\u2019inhibiteurs de la HMG-CoA. Hypersensibilit\u00e9 au principe actif ou \u00e0 l\u2019un des excipients. <strong>Pr: <\/strong>Les comprim\u00e9s et la suspension buvable ne sont pas interchangeables. Patients hypersensibles \u00e0 d\u2019autres antifongiques azol\u00e9s ; insuffisance h\u00e9patique s\u00e9v\u00e8re, arythmies cardiaques, troubles \u00e9lectrolytiques, malabsorption du glucose\/galactose. Co-administration d\u2019autres m\u00e9dicaments m\u00e9tabolis\u00e9s par voie du CYP3A4, de rifabutine, de rifamycines, de certains anti\u00e9pileptiques (ph\u00e9nyto\u00efne, carbamaz\u00e9pine, ph\u00e9nobarbital, primidone), d\u2019\u00e9favirenz, de cim\u00e9tidine, de sirolimus ou de m\u00e9dicaments causant un allongement du QTc. Il faut \u00e9viter l\u2019utilisation concomitante avec les vinca-alcalo\u00efdes (\u00e9valuer les avantages et les risques, r\u00e9duire la dose du vinca-alcalo\u00efde si n\u00e9cessaire). Pseudohyperaldost\u00e9ronisme : surveiller pression art\u00e9rielle et taux de potassium. <strong>IA: <\/strong>Rifabutine, \u00e9favirenz, ph\u00e9nyto\u00efne, fosampr\u00e9navir, flucloxacilline, substrat du CYP3A4, alcalo\u00efdes de l\u2019ergot de seigle, inhibiteurs de la HMG-CoA r\u00e9ductase m\u00e9tabolis\u00e9s par voie du CYP3A4, vinca-alcalo\u00efdes, ciclosporine, tacrolimus, sirolimus, agents antir\u00e9troviraux, midazolam\/autres benzodiaz\u00e9pines m\u00e9tabolis\u00e9es par voie du CYP3A4, antagonistes calciques m\u00e9tabolis\u00e9s par voie du CYP3A4, digoxine, sulfonylur\u00e9es, macrolides. <strong>G\/A: <\/strong>Non recommand\u00e9. Contraception. L\u2019allaitement doit \u00eatre arr\u00eat\u00e9 avant le d\u00e9but du traitement. <strong>EI: <\/strong><em>Tr\u00e8s fr\u00e9quents:<\/em> Naus\u00e9es. <strong>P: <\/strong><em><u>Comprim\u00e9s :<\/u> <\/em>100 mg, 24 (2x 12) et 96 (8x 12) comprim\u00e9s ; <em><u>Suspension :<\/u> <\/em>40 mg\/ml, flacon de 105 ml ; <em><u>Flacon-ampoule :<\/u> <\/em>concentr\u00e9 de 18 mg\/ml, flacon de 16,7 ml. <strong>CR: <\/strong>B. <strong>Td\u2019a<\/strong>: MSD Merck Sharp &amp; Dohme AG, Werftestrasse 4, 6005 Lucerne; (V5.0); CH-POS-00007.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\" \/>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color has-gray-800-color has-text-color has-link-color wp-elements-fe079b9928a396f2aa5cb5faf51ad0c3   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1a0ba380092e12407321ed517271cf8d\"><em>Avant de prescrire, veuillez consulter l\u2019information professionnelle compl\u00e8te publi\u00e9e sur la page d&rsquo;accueil de Swissmedic (<a href=\"https:\/\/www.swissmedicinfo-pro.ch\/ShowText.aspx?textType=FI&amp;lang=FR&amp;authNr=63240\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo-pro.ch<\/a>).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole) NOXAFIL\u00ae: PA: Posaconazole. I: Pr\u00e9vention des infections fongiques invasives, y compris par des levures [&hellip;]<\/p>\n","protected":false},"author":115978,"featured_media":0,"parent":96214,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","primary_tag":1608,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","mconnectIsArchiveTemplate":false,"mconnectArchiveFiltersDisabled":false,"mconnectArchiveLockAllPresetFilters":false,"mconnectArchiveHidePageSubmenu":false,"mconnectArchiveShowParentPageOnly":false,"mconnectArchiveDefaultOrder":"DESC","mconnectArchiveDefaultOrderBy":"date","mconnectArchivePostsPerPage":12,"mconnectArchivePostTypes":[],"mconnectArchiveAllowFilterBy":["category","tx-content-type","tx-product","tx-pathology","tx-active-ingredient","tx-therapeutic-area"],"mconnectArchiveTaxonomyOrder":[],"mconnectArchiveFilterSorting":["active","is_keyword","is_date"],"mconnectArchiveContentItemStyle":{"showExcerpt":true,"showImage":true,"showIcon":false,"showPrimaryTag":true,"showBorder":false,"showDates":false,"showCta":true,"isCard":false,"hasBackground":false,"showMetadata":true},"mconnectArchiveLayout":{"type":"list","hasFeatured":false},"mconnectDynamicTaxonomyEntities":[],"mconnectArchiveTerms_category":[],"mconnectArchiveAllowTerms_category":[],"mconnectArchiveTerms_tx-content-type":[],"mconnectArchiveAllowTerms_tx-content-type":[],"mconnectArchiveTerms_tx-product":[],"mconnectArchiveAllowTerms_tx-product":[],"mconnectArchiveTerms_tx-pathology":[],"mconnectArchiveAllowTerms_tx-pathology":[],"mconnectArchiveTerms_tx-active-ingredient":[],"mconnectArchiveAllowTerms_tx-active-ingredient":[],"mconnectArchiveTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_tx-therapeutic-area":[],"mconnectArchiveAllowTerms_dynamic-taxonomy":[],"mconnectArchiveLegacyDefaultTermsApplied":false,"mconnectContentUpdatesPerPage":10,"mconnectContentUpdatesViewMoreUrl":"","mconnectContentUpdatesTerms_tx-content-type":[],"mconnectContentUpdatesTerms_tx-product":[],"mconnectContentUpdatesTerms_tx-pathology":[],"mconnectContentUpdatesTerms_tx-active-ingredient":[],"mconnectContentUpdatesTerms_tx-therapeutic-area":[],"sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[1607],"tags":[1608],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[957],"ga4_page_businessunit":[962],"ga4_page_campaign":[],"ga4_page_content_purpose":[1535],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[1206],"ga4_page_product":[1342],"ga4_page_region":[1462],"ga4_page_therapeuticarea":[1513],"tx-therapeutic-area":[],"tx-product":[2305],"tx-pathology":[],"tx-content-type":[1609],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-103672","page","type-page","status-publish","hentry","category-kfi","tag-kfi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole) - MyMSD.ch FR<\/title>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole) - MyMSD.ch FR\" \/>\n<meta property=\"og:description\" content=\"Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole) NOXAFIL\u00ae: PA: Posaconazole. I: Pr\u00e9vention des infections fongiques invasives, y compris par des levures [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch FR\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T08:20:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2186\" \/>\n\t<meta property=\"og:image:height\" content=\"2134\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/\",\"name\":\"Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole) - MyMSD.ch FR\",\"isPartOf\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\"},\"datePublished\":\"2026-03-09T07:48:29+00:00\",\"dateModified\":\"2026-03-10T08:20:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Product Succinct Statement\",\"item\":\"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#website\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"name\":\"MyMSD.ch FR\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"contentUrl\":\"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png\",\"width\":4084,\"height\":692,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole) - MyMSD.ch FR","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"fr_FR","og_type":"article","og_title":"Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole) - MyMSD.ch FR","og_description":"Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole) NOXAFIL\u00ae: PA: Posaconazole. I: Pr\u00e9vention des infections fongiques invasives, y compris par des levures [&hellip;]","og_url":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/","og_site_name":"MyMSD.ch FR","article_modified_time":"2026-03-10T08:20:42+00:00","og_image":[{"width":2186,"height":2134,"url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2022\/03\/02852_MSD_Logo_W-Anthem_Vertical_TealGrey_RGB.png","type":"image\/png"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/","url":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/","name":"Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole) - MyMSD.ch FR","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/fr\/#website"},"datePublished":"2026-03-09T07:48:29+00:00","dateModified":"2026-03-10T08:20:42+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/noxafil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Product Succinct Statement","item":"https:\/\/www.mymsd.ch\/fr\/succinctstatement\/"},{"@type":"ListItem","position":3,"name":"Information professionnelle abr\u00e9g\u00e9e de NOXAFIL\u00ae (posaconazole)"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/fr\/#website","url":"https:\/\/www.mymsd.ch\/fr\/","name":"MyMSD.ch FR","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/fr\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","contentUrl":"https:\/\/www.mymsd.ch\/fr\/wp-content\/uploads\/sites\/30\/2023\/10\/cropped-myMSD-logo.png","width":4084,"height":692,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/103672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/users\/115978"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/comments?post=103672"}],"version-history":[{"count":2,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/103672\/revisions"}],"predecessor-version":[{"id":103702,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/103672\/revisions\/103702"}],"up":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/pages\/96214"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/media?parent=103672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/categories?post=103672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tags?post=103672"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_audience?post=103672"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_birn_id?post=103672"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_branding?post=103672"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_businessunit?post=103672"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_campaign?post=103672"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=103672"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=103672"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=103672"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_experience?post=103672"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_indication?post=103672"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_material_intent?post=103672"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_product?post=103672"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_region?post=103672"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=103672"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-therapeutic-area?post=103672"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-product?post=103672"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-pathology?post=103672"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-content-type?post=103672"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/tx-active-ingredient?post=103672"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/access?post=103672"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_status?post=103672"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/fr\/wp-json\/wp\/v2\/user_role?post=103672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}